DNA Adduct Assessment During Antihormonal Treatment of Perianal Gland Tumors With Tamoxifen in Male Dogs

Abstract

Background/Aim: Determination of DNA adduct count was performed in mononuclear cells during antihormonal treatment of perianal gland tumors. Materials and Methods: Eight-to fifteen-year-old dogs with carcinoma (CAR Group; N=5), epithelioma (EPI Group; N=16) or adenoma (ADE Group; N=24) were used. The control group suffered from perineal hernia or rectal diverticulum (CTR Group; N=25). Blood was collected at baseline, and at one and six months after the beginning of the anti-hormonal treatment with tamoxifen (1 mg/kg of body weight). DNA adduct count was determined using autoradiography. Results: At baseline, DNA adduct count reached the highest value in the CTR Group, and the lowest in the EPI Group (p<0.05). Sixmonth-long therapy with tamoxifen resulted in a significant increase in the DNA adduct count by 78.7%, 221.5% and 198.3% in the ADE, EPI and CAR groups, respectively (p<0.05). Conclusion: Increased DNA adduct formation after long-term administration of tamoxifen shows its genotoxicity. Perianal glands in dogs are considered as modified sebaceous glands located in the skin of the perianal region, perineum, prepuce, internal femoral region, lower surface of the tail and occasionally in other regions of the body. The development of perianal gland tumors is associated with stimulatory action of androgens and estrogens (1). Perianal gland hyperplasia 731 This article is freely accessible online.

Pharmacological Treatment of Perianal Gland Tumors in Male Dogs

“…They are second only to skin and testicular tumors [1,2]. According to the literature, they account for 9-18% of all skin cancers reported in male dogs [3][4][5][6][7]. The literature shows that tumors of the perianal region are among the hormone-dependent tumors to both androgens and estrogens.…”